Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: Wharf Rat who wrote (164691)	5/19/2020 1:02:43 PM
From: combjelly	Respond to of 362106

It is funny how he pretends ignorance of things he has actually discussed. Sort of like his cult leader.

To: Wharf Rat who wrote (164691)	5/19/2020 1:12:18 PM
From: i-node	Read Replies (1) \| Respond to of 362106

Let me back up. I've not heard that the problem is the dosage in the cardiac problem. My understanding is if you have the cardiac precondition the HCQ might trigger the deadly cardiac problem. So, as with all drugs, the doctor must screen for that unusual risk factor. But overdosing the patient -- as was done in Brazil -- will kill them. With a long HL if you continue to give the patient the loading dose beyond its half life you're eventually going to reach a point where the level becomes toxic. In Brazil they continued to give the loading dose for something like a week and they started losing an inordinate number of patients. TO BE CLEAR: This anomaly is present in about 0.000047 people, so it is exceedingly rare. And not all those people are going to die if given HCQ. And it can apparently be caught before the fact on an EKG, which the doctor would be expected to do. The drug isn't killing people.